Boston Scientific Corp. - BSX STOCK NEWS

Boston Scientific (NYSE: BSX) announced the limited release of the WaveWriter Alpha™ Spinal Cord Stimulator (SCS) systems. This portfolio includes four MRI conditional, Bluetooth-enabled implantable pulse generators (IPGs) that promise personalized pain relief through Fast Acting Sub-perception Therapy (FAST™). Currently, chronic pain affects over 50 million Americans, and traditional therapies can take longer to act. The FDA approved these systems in December 2020, indicating their use in managing chronic intractable pain, including conditions like Complex Regional Pain Syndrome.

Boston Scientific Corporation (NYSE: BSX) reported preliminary fourth-quarter 2020 net sales of approximately $2.71 billion, a decline of about 6.8% year-over-year. For the full year, net sales totaled approximately $9.91 billion, down 7.7%. Key challenges included a significant drop in WATCHMAN™ device sales due to inventory model changes, impacting organic growth by 8% in Q4. Some segments like Peripheral Interventions saw growth (4.8% organic), while Cardiovascular reported a significant decline of 12%. The company expects to discuss these results in detail during upcoming earnings calls.

Boston Scientific Corporation (NYSE: BSX) will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 8:20 a.m. EST. CEO Mike Mahoney will present, followed by a Q&A session with other executives, including Dan Brennan and Dr. Ian Meredith. On February 3, 2021, the company will hold a webcast at 8:00 a.m. EST to discuss its fourth-quarter financial results, announcing earnings prior to the call. The events will be available for live streaming and replay on their investor relations website.

Boston Scientific (NYSE: BSX) announced the sale of its BTG Specialty Pharmaceuticals business to SERB for $800 million in cash. The divestiture aims to enhance the BTG business's potential within specialty pharmaceuticals, particularly in life-saving antidotes. The BTG Specialty Pharmaceuticals is projected to generate $210 million in revenue for 2020. This sale follows the acquisition of BTG for approximately $3.7 billion, resulting in over $1 billion in net proceeds from divested businesses. The transaction is expected to close in H1 2021, pending regulatory approvals.

Boston Scientific Corporation (NYSE: BSX) will present at the 2020 Evercore ISI HealthCONx Conference on December 1. The session will feature CEO Mike Mahoney and VP of Investor Relations Susie Lisa, starting at approximately 8:00 a.m. EST. A live webcast and replay of the event will be available at investors.bostonscientific.com, accessible one hour after the session concludes. Boston Scientific is a leader in medical technology, providing innovative solutions that enhance patient care globally.

Boston Scientific (BSX) has announced a global voluntary recall of all unused LOTUS Edge Aortic Valve System inventory due to complexities with its delivery system. This recall will not affect patients who already have the valve implanted. The company will retire the entire LOTUS product platform, ceasing all related activities. This decision is estimated to incur pre-tax GAAP charges of $225 million to $300 million, with a significant portion impacting adjusted results. The expected effect on earnings per share for 2021 is a slight increase of 1 to 2 cents.

Boston Scientific Corporation (NYSE: BSX) will participate in two virtual investor conferences in November 2020. On November 12, Meghan Scanlon and Susie Lisa will engage in a Q&A session at the Credit Suisse Virtual Healthcare Conference at 8:00 a.m. EST. On November 18, Dan Brennan and Susie Lisa will take part in a Q&A at the Stifel 2020 Virtual Healthcare Conference starting at 8:40 a.m. EST. Live webcasts will be available at investors.bostonscientific.com, with replays accessible an hour after each event.

Boston Scientific (BSX) has received FDA approval for the Ranger™ Drug-Coated Balloon, aimed at treating peripheral artery disease (PAD) in the superficial femoral and proximal popliteal arteries. With around 200 million affected globally, the Ranger DCB features a low therapeutic drug dose, resulting in high primary patency rates and reduced systemic drug exposure. In pivotal trials, it achieved 94.1% major adverse event freedom and an 82.9% primary patency rate at 12 months, outperforming standard treatments. The device is set to launch in the US following its CE mark in 2014.

Boston Scientific (NYSE: BSX) has launched the CHAMPION-AF clinical trial to assess the safety and effectiveness of the WATCHMAN FLX™ device for patients with non-valvular atrial fibrillation (NVAF). This study will involve 3,000 patients at about 150 sites globally, comparing the device against non-vitamin K antagonist oral anticoagulants (NOACs). The trial aims to provide evidence for making the WATCHMAN FLX a potential first-line therapy for stroke prevention. The device offers a one-time solution, crucial for patients who cannot tolerate long-term anticoagulation.